Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo ...Middle East

News by : (PR Newswire) -
Duality to grant license of DITAC (Duality Immune Toxin Antibody Conjugates) platform to Adcendo for its lead uPARAP ADC program Duality to receive upfront payment, development, regulatory and commercial milestones, and tiered royalties Collaboration based on synergies between Adcendo and...

Read More Details
Finally We wish PressBee provided you with enough information of ( Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo )

Also on site :

Most Viewed News
جديد الاخبار